Skip to main content

Displaying 1061 - 1080 of 1208

Announced Actions for November 22, 2002

Date
The Commission has approved four applications from America Online/Time Warner, Inc. (AOLTW) requesting approval of non-affiliated Internet Service Providers (ISPs) and alternative cable broadband...

America Online, Inc., and Time Warner Inc.

AOL and Time Warner Inc. settled Commission concerns relating to their proposed merger. The order requires AOL Time Warner to open its cable system to competitor internet service providers. In addition, the company is prohibited from interfering with content passed along the bandwidth contracted for by non- affiliated internet service providers; and prohibited from interfering with the ability of non- affiliated providers of interactive television services to interact with interactive signals that AOL Time Warner agreed to carry.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
0010105
Docket Number
C-3989

Announced Actions for July 24, 2002

Date
The Commission has received two applications from America Online/Time Warner, Inc. (AOLTW) requesting approval of non-affiliated Internet Service Providers (ISPs) and alternative cable broadband...

FTC Issues Complaint Against Rambus, Inc.

Date
The Federal Trade Commission has charged Rambus, Inc., based in Los Altos, California, with violating federal antitrust laws by deliberately engaging in a pattern of anticompetitive acts and practices...

Biovail Corporation

The Commission charged Biovail Corporation with illegally acquiring an exclusive patent license for Tiazac, a pharmaceutical used to treat high blood pressure and chronic chest pain. The complaint further alleged that Biovail, in an effort to maintain its monopoly, wrongfully listed the acquired license in the U.S. Food and Drug Administration’s “Orange Book” for the purpose of blocking generic competition to its branded Tiazac. The consent order requires Biovail to divest part of its exclusive rights to DOV; prohibits the firm from taking any action that would trigger additional statutory stays on final FDA approval of a generic form of Tiazac; and also prohibits Biovail from wrongfully listing any patents in the Orange Book for a product for which the company already has an New Drug Application from the FDA.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
011 0094
Docket Number
C-4060

FTC Protecting Children's Privacy Online

Date
On the second anniversary of the Children's Online Privacy Protection Rule, the Federal Trade Commission announced its sixth COPPA enforcement case together with new initiatives designed to enhance...